Soy for breast cancer survivors: A critical review of the literature

Journal of Nutrition

Volumn 131, Issue 11 SUPPL., 2001, Pages

  Messina, M J ^a   Loprinzi, C L ^a  

^a Nutrition Matters Inc   (United States)

Author keywords

Breast cancer patients; Genistein; Isoflavones; Risk; Soy; Survival

Indexed keywords

DAIDZEIN; ESTROGEN; ESTROGEN RECEPTOR; GENISTEIN; GLYCITEIN; ISOFLAVONE; PROGESTERONE; SOYBEAN PROTEIN;

BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CELL GROWTH; CONFERENCE PAPER; DOSE RESPONSE; ESTROGEN ACTIVITY; FOOD COMPOSITION; FOOD INTAKE; GROWTH INHIBITION; HORMONE SUBSTITUTION; HUMAN; IN VITRO STUDY; NONHUMAN; PREMENOPAUSE; PROTECTION; SOYBEAN; TUMOR GROWTH;

GLYCINE MAX; MINK CELL FOCUS-FORMING VIRUS;

EID: 0035160104     PISSN: 00223166     EISSN: None     Source Type: Journal    
DOI: 10.1093/jn/131.11.3095s     Document Type: Conference Paper

References (288)

1. Based soy food maker stays a nose above the competition
2. Phyto-oestrogens and Western diseases
3. Soy, its components, and cancer prevention: A review of the in vitro, animal, and human data
4. Soy intake and cancer risk: A review of the in vitro and in vivo data
5. Soy protein, soybean isoflavones, and bone health: A review of the animal and human data
6. Phytoestrogens and bone
7. Soy protein and cardiovascular disease: A statement for healthcare professionals from the nutrition committee of the AHA
8. Food labeling, health claims, soy protein, and coronary heart disease
9. The role of soy products in reducing risk of cancer
10. HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids
11. Daidzein and genistein content of fruits and nuts
12. Daidzein and genistein contents of vegetables
13. Isoflavones in retail and institutional soy foods
14. Phytoestrogens and healthy aging: Gaps in knowledge. A workshop report
15. Selective estrogen receptor modulators: Structure, function, and clinical use
16. Phytoestrogens: The "natural" selective estrogen receptor modulators?
17. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens
18. Use and specificity of genistein as inhibitor of protein-tyrosine kinases
19. Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action
20. Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways
21. The climacteric, osteoporosis and hormone replacement; views of women aged 45-49
22. Why do postmenopausal women discontinue hormone replacement therapy?
23. Oral estrogen replacement therapy versus placebo for hot flushes: A systematic review
24. Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study
25. Use of hormone replacement therapy by postmenopausal women in the United States
26. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women
27. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study
28. Hormones to prevent coronary disease in women: When are observational studies adequate evidence?
29. HRT and heart disease: Dr Jekyll or Mrs Hyde?
30. Effects of hormone replacement therapy on clinical fractures and height loss: The heart and estrogen/progestin replacement study (HERS)
31. Postmenopausal hormone therapy for prevention of fractures. How good is the evidence?
32. Alternative therapies used by women with breast cancer in four ethnic populations
33. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites
34. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy
35. Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management, and relation to quality of life
36. Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk
37. Genistein: Does it prevent or promote breast cancer?
38. Nutrition during and after cancer treatment: A guide for informed choices by cancer survivors
39. Position of the American Dietetic Association and Dietitians of Canada: Women's health and nutrition
40. Use of botanicals for management of menopausal symptoms
41. Soybeans inhibit mammary tumors in models of breast cancer
42. High-fat diets and breast cancer risk. The epidemiologic evidence
43. Dietary factors and risk of breast cancer: Combined analysis of 12 case-control studies
44. Future possibilities in the prevention of breast cancer: Fat and fiber and breast cancer research
45. Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer
46. Association of dietary intake of fat and fatty acids with risk of breast cancer
47. Re: Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer
48. Dietary fiber and breast cancer
49. Intake of fruits and vegetables and risk of breast cancer: A pooled analysis of cohort studies
50. Dietary effects on breast-cancer risk in Singapore
51. The interaction in the immature mouse of potent oestrogens with coumestrol, genistein and other utero-vaginotrophic compounds of low potency
52. A specific inhibitor for tyrosine protein kinase from pseudomonas
53. Genistein, a specific inhibitor of tyrosine-specific protein kinases
54. Protein-tyrosine kinases
55. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein
56. Isoflavone composition of American and Japanese soybeans in lowa: Effects of variety, crop year, and location
57. Isoflavone content in Brazilian soybean cultivars
58. Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake
59. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women
60. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women
61. Dietary intake and sources of isoflavones among Japanese
62. Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice
63. Bioavailability of soybean isoflavones depends upon gut microflora in women
64. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women
65. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako)
66. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans
67. Plasma concentrations of phyto-oestrogens in Japanese men
68. Phytoestrogens and diseases of the prostate gland
69. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients
70. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein
71. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones
72. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements
73. In vitro bioassays of non-steroidal phytoestrogens
74. Validation of two in vitro test systems for estrogenic activities with zearalenone, phytoestrogens and cereal extracts
75. The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: Physiology of delivery modifies estrogenic activity
76. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17β-estradiol
77. Differentiation between vasculo-protective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta
78. Soy isoflavones exert modest hormonal effects in premenopausal women
79. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study
80. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats
81. Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet
82. Ethnic differences in post-menopausal plasma oestrogen levels: High oestrone levels in Japanese-American women despite low weight
83. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women
84. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women
85. Soy isoflavone supplementation in healthy men prevents NF-κB activation by TNF-α in blood lymphocytes
86. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
87. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta
88. Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors alpha and beta in vitro
89. Phyto-oestrogens through the life cycle
90. Therapeutic potential of selective estrogen receptor modulators
91. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
92. Development of QSAR models to predict estrogenic, carcinogenic, and cancer protective effects of phytoestrogens
93. Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium
94. Dietary estrogens stimulate human breast cells to enter the cell cycle
95. Dietary estrogens act through estrogen receptor-mediated processes and show no antiestrogenicity in cultured breast cancer cells
96. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro
97. The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function
98. Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells
99. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists
100. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study
101. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens
102. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes
103. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens?
104. Inhibition of 17β-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells
105. Effects of phytoestrogens on aromatase, 3β and 17β-hydroxysteroid dehydrogenase activities and human breast cancer cells
106. Estrogen and the risk of breast cancer
107. Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer
108. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques
109. Regulation of signal transduction activity in normal and cancer cells
110. Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by low density lipoprotein particles into cultured U937 cells
111. Antioxidant activity of phytoestrogenic isoflavones
112. Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multidrug resistance gene
113. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells
114. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells
115. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo
116. Genistein's "ER-dependent and independent" actions are mediated through ER pathways in ER-positive breast carcinoma cell lines
117. Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro
118. Induction of apoptosis and inhibition of C-ERBB-2 in MDA-MB-435 cells by genistein
119. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells
120. Genistein exerts multiple suppressive effects on human breast carcinoma cells
121. Bcl-2 is not reduced in the death of MCF-7 cells at low genistein concentration
122. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis
123. Genistein in the control of breast cancer cell growth: Insights into the mechanism of action in vitro
124. Antiestrogens are partial estrogen agonists for prolactin production in primary pituitary cultures
125. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors
126. Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein
127. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines
128. Genistein, a component of soy, inhibits the expression of the EGF and ERBB2/NEU receptors in the rat dorsolateral prostate
129. Mass spectrometric determination of genistein tissue distribution in diet-exposed Sprague-Dawley rats
130. Genistein, a dietary-derived inhibitor of in vitro angiogenesis
131. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis
132. Effects of genistein and 2-methoxyestradiol on matrix metalloproteinases and their inhibitors secreted by Ehrlich ascites tumor cells
133. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice
134. Soybean isoflavones reduce experimental metastasis in mice
135. Genistein attenuates peritoneal metastasis of azoxymethane-induced intestinal adenocarcinomas in wistar rats
136. Effect of dietary supplementation of soybeans on experimental metastasis of melanoma cells in mice
137. Effect of isoflavones genistein and daidzein in the inhibition of lung metastasis in mice induced by B16F-10 melanoma cells
138. Diets containing whey proteins or soy protein isolate protect against 7, 12-dimethylbenz(a)anthracene-induced mammary tumors in female rats
139. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A
140. Dietary soybean isolate and methionine supplementation affect mammary tumor progression in rats
141. Effect of miso (Japanese soybean paste) and NaCl on DMBA-induced rat mammary tumors
142. Inhibitory effects of bifidobacterium-fermented soy milk on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinogenesis, with a partial contribution of its component isoflavones
143. Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis
144. Experimental evidence of dietary factors and hormone-dependent cancers
145. Modification of spontaneous mammary tumors in mice fed different sources of protein, fat and carbohydrate
146. Quality of dietary protein during initiation and promotion of chemical carcinogenesis in rats
147. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination
148. Potential role of dietary isoflavones in the prevention of cancer
149. Antitumor effects of soybean hypocotyls and soybeans on the mammary tumor induction by N-methyl-N-nitrosourea in F344 rats
150. Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones
151. The antitumorigenic properties of ipriflavone and genistin in rat mammary tissues
152. Factors affecting isoflavone content in soybean seeds: Changes in isoflavones, saponins, and composition of fatty acids at different temperatures during seed development
153. Animal models impacted by phytoestrogens in commercial chow: Implications for pathways influenced by hormones
154. Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women
155. Interindividual variation in metabolism of soy isoflavones and lignans: Influence of habitual diet on equol production by the gut microflora
156. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer
157. Nonsteroidal estrogens of dietary origin: Possible roles in hormone-dependent disease
158. Effects of isoflavonoids on blood pressure in subjects with high-normal ambulatory blood pressure levels: A randomized controlled trial
159. The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A
160. Dietary genistein increased DMBA-induced mammary adenocarcinoma in wild-type but not ERα KO mice
161. Soy and experimental cancer: Animal studies
162. Molecular mechanisms of cell cycle block by methionine restriction in human prostate cancer cells
163. Ecological study of the association between soy protein intake and mortality from cancer and heart disease in Japan
164. The effects of a soybean extract on tumor growth and metastasis
165. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner
166. Dietary soybean may be antiestrogenic in male mice
167. Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice
168. Endometrium and plasma hormone profile in the perimenopause and post-menopause
169. Functional role of estrogen metabolism in target cells: Review and perspectives
170. Concentration of sex steroids in adipose tissue after menopause
171. Protection against breast cancer with genistein: A component of soy
172. Neonatal genistein chemoprevents mammary cancer
173. Genistein suppresses mammary cancer in rats
174. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats
175. Dietary genistein: Perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat
176. Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
177. DNA labeling index and structure of the rat mammary gland as determinants of its susceptibility to carcinogenesis
178. Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone
179. Susceptibility of the mammary gland to carcinogenesis: I Differentiation of the mammary gland as determinant of tumor incidence and type of lesion
180. Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy
181. Age at first birth and breast cancer risk
182. Maternal genistein exposure mimics the effects of estrogen on mammary gland development in female mouse offspring
183. Maternal and prepubertal diet, mammary development and breast cancer risk
184. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring
185. Some international differences in treatment and survival in breast cancer
186. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products
187. Ethnic differences and factors related to breast cancer survival in Hawaii
188. Breast cancer in Japan and United States: Epidemiology, hormone receptors, pathology, and survival
189. Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer
190. Estimates of the worldwide mortality from 25 cancers in 1990
191. Meta-analysis of soy intake and breast cancer risk
192. Diet and breast cancer in Shanghai and Tianjin, China
193. Occurrence of breast cancer in relation to diet and reproductive history: A case-control study in Fukuoka, Japan
194. Breast cancer and diet among the Japanese in Hawaii
195. Soya foods and breast cancer risk: A prospective study in Hiroshima and Nagasaki, Japan
196. A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status
197. Soybean products, vegetable and fruit and breast cancer risk in Taiwan
198. Tofu and risk of breast cancer in Asian-Americans
199. Evolution of meal patterns and food choices of Japanese-American females born in the United States
200. Assessing phytoestrogen exposure in epidemiologic studies: Development of a database (United States)
201. Nutrient intakes in an ethnically diverse sample of US women
202. Soy intake and risk of breast cancer in Asians and Asian Americans
203. Case-control study of phyto-oestrogens and breast cancer
204. Phytoestrogens and breast cancer in postmenopausal women: A case control study
205. Risk of breast cancer associated with intake of specific foods and food groups
206. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women
207. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles county
208. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women
209. Effects of soya consumption for one month on steroid hormones in premenopausal women: Implications for breast cancer risk reduction
210. Short-term effect of phytoestrogen-rich diet on postmenopausal women
211. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women
212. Biological effects of isoflavones in young women: Importance of the chemical composition of soyabean products
213. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women
214. Effects of soy intake on sex hormone metabolism in premenopausal women
215. Effects of soy foods on ovarian function in premenopausal women
216. Modest hormonal effects of soy isoflavones in postmenopausal women
217. Soy consumption alters endogenous estrogen metabolism in postmenopausal women
218. Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones
219. Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women
220. Regulation of sex hormone-binding globulin production by isoflavonoids and patterns of isoflavonoid conjugation in HEP G2 cell cultures
221. Dietary phytoestrogens and cancer: In vitro and in vivo studies
222. Dietary isoflavones affect sex hormone-binding globulin levels in postmenopausal women
223. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation
224. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women
225. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males
226. The effects of soy protein in women and men with elevated plasma lipids
227. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women
228. Decreased ovarian hormones during a soya diet: Implications for breast cancer prevention
229. Nipple aspirate fluid in epidemiologic studies of breast disease
230. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid
231. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy
232. Birthplace and yield of nipple aspirate fluid in Chinese women
233. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast
234. Increased cell division as a cause of human cancer
235. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis
236. Balance of cell proliferation and apoptosis in breast carcinogenesis
237. Soy, soy phytoestrogens (isoflavones), and breast cancer
238. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast
239. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States)
240. Mammographic density as a marker of susceptibility to breast cancer: A hypothesis
241. Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention
242. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern
243. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer
244. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
245. Endogenous estrogen and postmenopausal breast cancer: A quantitative review
246. International variability in ages at menarche, first livebirth, and menopause. World Health Organization collaborative study of neoplasia and steroid contraceptives
247. Bone mineral density and breast cancer risk in postmenopausal women
248. Bone mass and the risk of breast cancer among postmenopausal women
249. Bone mineral density and risk of breast cancer: Differences by family history of breast cancer
250. Association between breast cancer and bone mineral density: The Dubbo osteoporosis epidemiology study
251. Bone mass and breast cancer risk in older women: Differences by stage at diagnosis
252. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients
253. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer
254. Treatment of oestrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement
255. Estrogen deficiency: In search of symptom control and sexuality
256. Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively
257. Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study
258. Hormone replacement therapy and high S phase in breast cancer
259. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy
260. Prognosis of breast cancers detected in women receiving hormone replacement therapy
261. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality
262. Estrogen-progestin replacement and risk of breast cancer
263. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
264. Response: Re: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
265. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
266. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy
267. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
268. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
269. Proliferation of breast epithelial cells in healthy women during the menstrual cycle
270. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast
271. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques
272. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology
273. Mammographic breast density during hormone replacement therapy: Differences according to treatment
274. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
275. Mammographic breast density during hormone replacement therapy: Effects of continuous combination, unopposed transdermal and low-potency estrogen regimens
276. Lifestyle, hormones, and risk of breast cancer
277. Estrogen and progestin bioactivity of foods, herbs, and spices
278. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes
279. Anabolic effect of genistein in osteoblastic MC3T3-E1 cells
280. Stimulatory effect of daidzein in osteoblastic MC3T3-E1 cells
281. Soybean ethanol extract increases the function of osteoblastic MC3T3-E1 cells
282. Consumption of soy products may enhance tamoxifen's breast cancer preventive effects
283. Phytoestrogens for menopause
284. The role of isoflavones in menopausal health: Consensus opinion of the North American Menopause Society
285. Soy protein and cardiovascular disease: The impact of bioactive components in soy
286. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins
287. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen